This article is more than 5 years old. Information may no longer be current.
Iris-claw phakic IOL shows good long-term results
Click Here to Manage Email Alerts
In the long term, implantation of an iris-claw phakic IOL can be considered a safe, effective, stable and reversible procedure, according to 5-year results from a retrospective study in Spain.
Jose L. Güell, MD, and colleagues at Instituto de Microcirugia Ocular, Barcelona, and Autonoma University of Barcelona evaluated results after implanting a total of 399 Artisan phakic IOLs (Ophtec) between January 1996 and January 2003. Specifically, 101 patients received 5-mm optic phakic IOLs (group one), 173 patients received 6-mm optic phakic IOLs (group two), 41 patients received phakic IOLs to correct hyperopia (group three) and 84 patients received toric phakic IOLs (group four).
The investigators measured manifest refraction, uncorrected visual acuity, best corrected visual acuity, biomicroscopy, tonometry, funduscopy and central endothelial cell counts at baseline, 3 months and annually for an average of 4.05 years' follow-up.
In these patients, respective baseline and final postoperative spherical equivalents averaged –19.8 D and –0.5 D in group one, –11.27 D and –0.64 D in group two, +4.92 D and +0.02 D in group three and –6.82 D and –0.09 D in group four.
At baseline, patients in group four had an average of –3.24 D of cylinder, which decreased to –0.83 D postoperatively, the authors noted.
Additional keratorefractive surgery was performed in 60.39% of eyes in group one, 19.6% of eyes in group two, 41.4% of eyes in group three and 5.95% of eyes in group four.
Baseline and final postoperative endothelial cell counts averaged 2,836 cells/mm² and 2,514 cells/mm² in group one, 2,755 cells/mm² and 2,454 cells/mm² in group two, 2,735 cells/mm² and 2,560 cells/mm² in group three, and 2,632 cells/mm² and 2,537 cells/mm² in group four.
The investigators reported three explantations due to unacceptable drops in endothelial cell count and three lens repositionings, two due to ocular trauma and one due to inappropriate iris capture. In addition, the investigators reported three lens exchanges due to refractive errors, one macular hemorrhage, one retinal detachment and two cataracts, according to the study, published in the June issue of Ophthalmology.
Advanced Medical Optics markets the Artisan IOL in the United States under the trade name Verisyse.